{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=47", "query": { "intervention": "serum sample", "page": 47 }, "page_size": 10 }, "pagination": { "page": 47, "page_size": 10, "total_count": 8374, "total_pages": 838, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=48&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=46&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T04:07:42.119Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04702880", "title": "A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive-stage Small Cell Lung Cancer" ], "interventions": [ { "name": "BMS-986012", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2021-03-17", "completion_date": "2025-11-28", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Hackensack, New Jersey • Durham, North Carolina + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04702880" }, { "nct_id": "NCT02889796", "title": "Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "Placebo to match filgotinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo to match adalimumab", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1759, "start_date": "2016-08-30", "completion_date": "2019-06-20", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 48, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Hemet", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02889796" }, { "nct_id": "NCT02669173", "title": "Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2016-10-11", "completion_date": "2025-01-07", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02669173" }, { "nct_id": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "DB-1310", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2023-08-17", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 15, "location_summary": "Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785741" }, { "nct_id": "NCT05032183", "title": "Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent T Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Lymphoblastic Lymphoma", "Refractory T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tagraxofusp-erzs", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2022-02-17", "completion_date": "2024-07-31", "has_results": true, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05032183" }, { "nct_id": "NCT03712202", "title": "Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage I Hodgkin Lymphoma", "Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma", "Ann Arbor Stage IA Hodgkin Lymphoma", "Ann Arbor Stage IB Hodgkin Lymphoma", "Ann Arbor Stage II Hodgkin Lymphoma", "Ann Arbor Stage IIA Hodgkin Lymphoma", "Ann Arbor Stage IIB Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lymphocyte-Rich Classic Hodgkin Lymphoma", "Ann Arbor Stage I Lymphocyte-Depleted Classic HL", "Ann Arbor Stage II Lymphocyte-Depleted Classic HL", "Ann Arbor Stage II Mixed Cellularity Classic HL", "Ann Arbor Stage II Nodular Sclerosis Classic HL" ], "interventions": [ { "name": "Bleomycin", "type": "DRUG" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Vinblastine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 155, "start_date": "2018-11-28", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Duarte, California • San Diego, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03712202" }, { "nct_id": "NCT01175395", "title": "20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "IBI-20089/Lucentis", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 10, "start_date": "2010-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01175395" }, { "nct_id": "NCT01445327", "title": "Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophageal Cancer", "Stomach Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Specimen collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2007-02-20", "completion_date": "2014-05-22", "has_results": true, "last_update_posted_date": "2022-02-01", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445327" }, { "nct_id": "NCT03623854", "title": "Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chordoma", "Locally Advanced Chordoma", "Metastatic Chordoma", "Unresectable Chordoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 10, "start_date": "2019-04-03", "completion_date": "2023-09-28", "has_results": false, "last_update_posted_date": "2024-04-16", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03623854" }, { "nct_id": "NCT00178451", "title": "Stroke Prevention With Abciximab in Carotid Endarterectomy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carotid Stenosis" ], "interventions": [ { "name": "Abciximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2015-12-18", "last_synced_at": "2026-10-24T04:07:42.119Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00178451" } ] }